 Christopher Raeburn
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 11 | 2022 | 269 | 1.270 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 82 | 1.040 |
Why?
| | Pancreatic Neoplasms | 3 | 2022 | 771 | 0.690 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2022 | 36 | 0.660 |
Why?
| | Intercellular Adhesion Molecule-1 | 5 | 2011 | 177 | 0.500 |
Why?
| | Ischemic Preconditioning | 2 | 2004 | 31 | 0.460 |
Why?
| | Diiodothyronines | 1 | 2011 | 4 | 0.420 |
Why?
| | Propionates | 1 | 2011 | 37 | 0.410 |
Why?
| | Myocardial Ischemia | 2 | 2011 | 270 | 0.400 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2010 | 1176 | 0.390 |
Why?
| | Heart | 3 | 2004 | 671 | 0.380 |
Why?
| | Delirium | 4 | 2014 | 69 | 0.370 |
Why?
| | Myocarditis | 1 | 2011 | 96 | 0.370 |
Why?
| | Technetium Tc 99m Sestamibi | 3 | 2015 | 13 | 0.370 |
Why?
| | Parathyroid Glands | 3 | 2015 | 9 | 0.370 |
Why?
| | Ischemic Preconditioning, Myocardial | 4 | 2010 | 33 | 0.370 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 207 | 0.360 |
Why?
| | Surgical Procedures, Operative | 2 | 2002 | 230 | 0.360 |
Why?
| | Lipopolysaccharides | 5 | 2002 | 861 | 0.340 |
Why?
| | Thyroidectomy | 5 | 2018 | 53 | 0.340 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2016 | 195 | 0.330 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 205 | 0.320 |
Why?
| | Adrenocortical Carcinoma | 2 | 2018 | 51 | 0.310 |
Why?
| | Postoperative Complications | 8 | 2023 | 2322 | 0.290 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 368 | 0.290 |
Why?
| | Shock, Hemorrhagic | 3 | 2004 | 241 | 0.290 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2002 | 44 | 0.280 |
Why?
| | Radionuclide Imaging | 3 | 2013 | 141 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2003 | 148 | 0.270 |
Why?
| | Myocardial Infarction | 2 | 2011 | 1142 | 0.270 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2021 | 81 | 0.260 |
Why?
| | Hypocalcemia | 2 | 2015 | 32 | 0.250 |
Why?
| | Neutrophils | 6 | 2011 | 1252 | 0.250 |
Why?
| | Biomarkers, Tumor | 4 | 2021 | 1075 | 0.240 |
Why?
| | Iodine Radioisotopes | 4 | 2022 | 129 | 0.240 |
Why?
| | Carcinoma, Neuroendocrine | 3 | 2022 | 29 | 0.240 |
Why?
| | Drosophila Proteins | 2 | 2002 | 172 | 0.240 |
Why?
| | Antigens, CD | 2 | 2003 | 468 | 0.240 |
Why?
| | Osteitis Fibrosa Cystica | 1 | 2002 | 1 | 0.230 |
Why?
| | Thyroxine | 1 | 2023 | 64 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 2002 | 450 | 0.230 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 12 | 0.230 |
Why?
| | Endotoxemia | 2 | 2010 | 92 | 0.230 |
Why?
| | Pheochromocytoma | 2 | 2021 | 52 | 0.230 |
Why?
| | Hypothyroidism | 1 | 2023 | 69 | 0.230 |
Why?
| | Thoracic Surgery | 1 | 2004 | 141 | 0.220 |
Why?
| | Iodine | 1 | 2022 | 23 | 0.220 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 101 | 0.220 |
Why?
| | Adenocarcinoma | 2 | 2022 | 833 | 0.220 |
Why?
| | Myocardium | 5 | 2011 | 1010 | 0.220 |
Why?
| | Chemokines | 4 | 2011 | 230 | 0.200 |
Why?
| | Tryptophan | 2 | 2014 | 137 | 0.200 |
Why?
| | Interleukin-18 | 1 | 2002 | 229 | 0.200 |
Why?
| | Adrenalectomy | 1 | 2000 | 80 | 0.190 |
Why?
| | Paraganglioma | 1 | 2021 | 46 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 154 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 175 | 0.190 |
Why?
| | Prognosis | 4 | 2022 | 3603 | 0.180 |
Why?
| | Abdominal Injuries | 1 | 2000 | 120 | 0.180 |
Why?
| | Humans | 41 | 2023 | 121869 | 0.170 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 33 | 0.170 |
Why?
| | Pancreatectomy | 1 | 2000 | 178 | 0.170 |
Why?
| | Trans-Activators | 1 | 2021 | 395 | 0.170 |
Why?
| | Stress, Physiological | 1 | 2002 | 431 | 0.170 |
Why?
| | Adrenal Cortex | 1 | 2018 | 37 | 0.160 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 245 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1200 | 0.160 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 31 | 0.160 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 50 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1438 | 0.150 |
Why?
| | Animals | 17 | 2021 | 34134 | 0.150 |
Why?
| | Carcinoma | 1 | 2018 | 213 | 0.150 |
Why?
| | Mice, Inbred C57BL | 6 | 2011 | 5054 | 0.150 |
Why?
| | Medical Oncology | 1 | 2018 | 229 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 877 | 0.140 |
Why?
| | Cytokines | 2 | 2015 | 1904 | 0.140 |
Why?
| | Adrenal Glands | 1 | 2016 | 75 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 113 | 0.140 |
Why?
| | Virus Latency | 1 | 2016 | 82 | 0.140 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 3 | 2004 | 80 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 107 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 428 | 0.130 |
Why?
| | Mice | 12 | 2019 | 15621 | 0.130 |
Why?
| | Multimodal Imaging | 1 | 2015 | 104 | 0.130 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2014 | 38 | 0.130 |
Why?
| | Islets of Langerhans | 1 | 2000 | 740 | 0.130 |
Why?
| | Elective Surgical Procedures | 2 | 2014 | 169 | 0.120 |
Why?
| | DNA, Viral | 1 | 2016 | 388 | 0.120 |
Why?
| | Carotid Artery Injuries | 2 | 2004 | 42 | 0.120 |
Why?
| | Tunica Intima | 2 | 2004 | 84 | 0.120 |
Why?
| | Subtraction Technique | 1 | 2013 | 26 | 0.120 |
Why?
| | Male | 24 | 2017 | 60475 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2016 | 707 | 0.120 |
Why?
| | Middle Aged | 16 | 2019 | 28961 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2015 | 357 | 0.110 |
Why?
| | Chemokine CCL2 | 2 | 2011 | 126 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2015 | 727 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2004 | 2727 | 0.110 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 382 | 0.110 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 2913 | 0.100 |
Why?
| | Carcinoma, Papillary | 1 | 2012 | 76 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 179 | 0.100 |
Why?
| | Patient Care Management | 1 | 2011 | 59 | 0.100 |
Why?
| | Cell Proliferation | 4 | 2021 | 2363 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 170 | 0.100 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 79 | 0.100 |
Why?
| | Antibodies | 2 | 2002 | 400 | 0.090 |
Why?
| | Vascular Surgical Procedures | 2 | 2004 | 278 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 77 | 0.090 |
Why?
| | Extracellular Space | 1 | 2010 | 133 | 0.090 |
Why?
| | Aged | 12 | 2019 | 20705 | 0.090 |
Why?
| | Calcium | 1 | 2015 | 1207 | 0.090 |
Why?
| | Endotoxins | 1 | 2010 | 239 | 0.090 |
Why?
| | Intestinal Perforation | 1 | 2008 | 44 | 0.090 |
Why?
| | Duodenum | 1 | 2008 | 63 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2011 | 3800 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 272 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1012 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1076 | 0.080 |
Why?
| | Acute Disease | 1 | 2011 | 986 | 0.080 |
Why?
| | Pancreatic Ducts | 1 | 2008 | 71 | 0.080 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 72 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2010 | 336 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2011 | 685 | 0.080 |
Why?
| | Female | 16 | 2021 | 63903 | 0.080 |
Why?
| | Macrophages | 2 | 2011 | 1328 | 0.080 |
Why?
| | Mutation | 4 | 2021 | 3520 | 0.070 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 180 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2008 | 198 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 958 | 0.070 |
Why?
| | Software | 1 | 2011 | 653 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2564 | 0.070 |
Why?
| | Carotid Arteries | 2 | 2004 | 191 | 0.070 |
Why?
| | Hyperplasia | 2 | 2004 | 169 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2519 | 0.070 |
Why?
| | Biopsy, Fine-Needle | 2 | 2017 | 69 | 0.070 |
Why?
| | Toll-Like Receptors | 2 | 2002 | 169 | 0.060 |
Why?
| | Transplantation | 1 | 2004 | 27 | 0.060 |
Why?
| | Vasculitis | 1 | 2004 | 76 | 0.060 |
Why?
| | Preoperative Care | 2 | 2011 | 344 | 0.060 |
Why?
| | Insulinoma | 1 | 2003 | 31 | 0.060 |
Why?
| | Signal Transduction | 3 | 2016 | 4810 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1871 | 0.060 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2004 | 170 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1237 | 0.060 |
Why?
| | Computers | 1 | 2023 | 69 | 0.060 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 11 | 0.060 |
Why?
| | Parathyroidectomy | 1 | 2002 | 7 | 0.060 |
Why?
| | Collateral Circulation | 1 | 2002 | 21 | 0.060 |
Why?
| | Thyrotropin | 1 | 2023 | 109 | 0.060 |
Why?
| | Risk Assessment | 3 | 2015 | 3248 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 466 | 0.060 |
Why?
| | Immunophenotyping | 2 | 2015 | 282 | 0.060 |
Why?
| | Neurosurgical Procedures | 1 | 2004 | 165 | 0.060 |
Why?
| | Vinblastine | 1 | 2002 | 69 | 0.060 |
Why?
| | Interleukin-10 | 1 | 2004 | 304 | 0.060 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 12 | 0.060 |
Why?
| | Mitochondria, Heart | 1 | 2002 | 87 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 591 | 0.050 |
Why?
| | Risk Factors | 5 | 2012 | 9419 | 0.050 |
Why?
| | Time Factors | 4 | 2015 | 6889 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 141 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2002 | 33 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2018 | 9654 | 0.050 |
Why?
| | Hemostatics | 1 | 2002 | 49 | 0.050 |
Why?
| | Vasopressins | 1 | 2002 | 68 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 316 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1738 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2002 | 410 | 0.050 |
Why?
| | Coronary Disease | 1 | 2004 | 396 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 18 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 191 | 0.050 |
Why?
| | Internship and Residency | 1 | 2011 | 1045 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2003 | 362 | 0.050 |
Why?
| | Adenoma | 1 | 2002 | 190 | 0.050 |
Why?
| | Indazoles | 1 | 2021 | 69 | 0.050 |
Why?
| | Lung | 3 | 2002 | 3767 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1137 | 0.050 |
Why?
| | Drug Synergism | 1 | 2021 | 340 | 0.050 |
Why?
| | Laparotomy | 1 | 2000 | 113 | 0.050 |
Why?
| | Neovascularization, Physiologic | 1 | 2001 | 188 | 0.050 |
Why?
| | Interleukins | 1 | 2002 | 242 | 0.050 |
Why?
| | Cardiovascular System | 1 | 2001 | 128 | 0.050 |
Why?
| | Military Medicine | 1 | 2000 | 73 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2001 | 292 | 0.050 |
Why?
| | Imidazoles | 1 | 2021 | 241 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 149 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 907 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2001 | 164 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 682 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 306 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 3 | 2010 | 340 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 33 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 6 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 7 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 449 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 17 | 0.040 |
Why?
| | Graft Rejection | 1 | 2002 | 600 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 327 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2018 | 82 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 248 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 285 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 769 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2016 | 6974 | 0.040 |
Why?
| | Reoperation | 1 | 2000 | 578 | 0.040 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2002 | 272 | 0.040 |
Why?
| | Homeostasis | 1 | 2002 | 608 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 46 | 0.040 |
Why?
| | NF-kappa B | 3 | 2010 | 672 | 0.040 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 14 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 984 | 0.040 |
Why?
| | Immunoblotting | 1 | 2018 | 317 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2000 | 779 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 345 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 134 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 494 | 0.040 |
Why?
| | Frozen Sections | 1 | 1996 | 25 | 0.040 |
Why?
| | Adult | 6 | 2016 | 32683 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2015 | 3314 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2023 | 13063 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 693 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2002 | 757 | 0.040 |
Why?
| | Tracheostomy | 1 | 1997 | 94 | 0.040 |
Why?
| | Laparoscopy | 1 | 2000 | 421 | 0.040 |
Why?
| | Prospective Studies | 3 | 2015 | 6629 | 0.040 |
Why?
| | Cricoid Cartilage | 1 | 2015 | 15 | 0.040 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2016 | 21 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 91 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 82 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 96 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 783 | 0.030 |
Why?
| | Herpes Simplex | 1 | 2016 | 93 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 147 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 30 | 0.030 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 80 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 135 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2582 | 0.030 |
Why?
| | Niacinamide | 1 | 2014 | 71 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 204 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 72 | 0.030 |
Why?
| | Paclitaxel | 1 | 2015 | 204 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 127 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 744 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 576 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2876 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 87 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 264 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 679 | 0.030 |
Why?
| | Doxorubicin | 1 | 2015 | 312 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2004 | 36 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 5 | 0.030 |
Why?
| | Melatonin | 1 | 2014 | 112 | 0.030 |
Why?
| | Neck Dissection | 1 | 2012 | 10 | 0.030 |
Why?
| | Incidence | 2 | 2011 | 2520 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1425 | 0.030 |
Why?
| | Postoperative Care | 1 | 2014 | 241 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1033 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2004 | 424 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2014 | 272 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 376 | 0.030 |
Why?
| | Preoperative Period | 1 | 2012 | 114 | 0.030 |
Why?
| | Serotonin | 1 | 2014 | 330 | 0.030 |
Why?
| | Inflammation | 1 | 2003 | 2522 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 1002 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 312 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1008 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 462 | 0.020 |
Why?
| | Intraoperative Period | 2 | 2003 | 59 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 91 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2002 | 1812 | 0.020 |
Why?
| | Workload | 1 | 2011 | 132 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2010 | 69 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2014 | 618 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 225 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1720 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 886 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2802 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 11223 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2011 | 187 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2012 | 468 | 0.020 |
Why?
| | Safety | 1 | 2011 | 313 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 987 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1574 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 104 | 0.020 |
Why?
| | Bile Ducts | 1 | 2008 | 73 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1108 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1069 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2241 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 300 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1383 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1356 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2037 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 1019 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 564 | 0.020 |
Why?
| | Cell Movement | 2 | 2001 | 909 | 0.020 |
Why?
| | Patient Readmission | 1 | 2012 | 678 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 528 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 884 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3078 | 0.020 |
Why?
| | Growth Substances | 1 | 2004 | 134 | 0.020 |
Why?
| | Protein Binding | 1 | 2010 | 2017 | 0.020 |
Why?
| | Survival Rate | 1 | 2008 | 1828 | 0.020 |
Why?
| | Age Factors | 1 | 2011 | 3173 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2999 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1399 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 99 | 0.010 |
Why?
| | Monokines | 1 | 2002 | 25 | 0.010 |
Why?
| | Chemokine CXCL2 | 1 | 2002 | 46 | 0.010 |
Why?
| | United States | 1 | 2018 | 13209 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 67 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 265 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 189 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 56 | 0.010 |
Why?
| | Lymphokines | 1 | 2001 | 124 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2002 | 132 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 289 | 0.010 |
Why?
| | Postoperative Period | 1 | 2002 | 323 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5300 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 236 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 853 | 0.010 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2002 | 221 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 633 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 387 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4883 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 4922 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 526 | 0.010 |
Why?
| | Colorado | 1 | 2008 | 4344 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 791 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 205 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 207 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 1996 | 189 | 0.010 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1997 | 153 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1530 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2001 | 706 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2746 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 560 | 0.010 |
Why?
| | Adolescent | 1 | 1997 | 19126 | 0.000 |
Why?
|
|
Raeburn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|